Schizophrenia medication withdrawal study
Treatments studied
Part of Mental health clinical trials.
This study tests whether patients with schizophrenia can safely stop or reduce their current medication without worsening symptoms. It is designed for people who need ongoing psychiatric care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with schizophrenia (based on standard diagnostic criteria).
- You need regular psychiatric treatment for your condition.
- You do not have another major mental health condition that required primary treatment in the last 6 months (e.g., bipolar disorder, major depression).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study checks how safe and well-tolerated iloperidone is when used in a typical, open-label way for teenagers. It may help doctors better understand side effects and safety in teens with schizophrenia or bipolar I disorder.
This is an observational (non-intervention) study that follows adults with schizophrenia who are taking specific “atypical” antipsychotic medicines long-term. Researchers want to learn about patients’ experiences and outcomes while on these treatments.
This trial is testing whether it is safe to slowly reduce or stop anticholinergic medications (benztropine or trihexyphenidyl) in people with schizophrenia. It aims to see if stopping these drugs can help with thinking and memory without causing worsening movement problems.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This trial asks people who have schizophrenia to share their experience doing study activities, and it tests whether the study procedures work well for patients. It may help improve how future schizophrenia studies are run.
This study tests whether a new medication that targets immune system inflammation (IL-23) can help people with schizophrenia feel better. Researchers believe this immune approach might reduce symptoms when combined with regular antipsychotic treatment.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.